ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.

May 4, 2001

NCI Director Says Gallo’s Work On HIV Should Have Been Recognized.

October 10, 2008

House, Senate Reform Bills Move Closer To Floor Vote

August 12, 1994

In Brief: Shingleton Probably Replacement For Marks On Panel; Connie Henke Heads Oncology Nurses

June 8, 1979

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

July 25, 1975

Greenwald: Report’s Implementation Will Require Budget Raise

June 27, 1997